Journal article
Rational design of a chimpanzee adenoviral-vector vaccine against yellow fever through the modification of antigen transmembrane domains
- Abstract:
-
Background/Objectives:
Chimpanzee adenoviral-vectored vaccines have proven to be both safe and effective, with a manufacturing and distribution pipeline capable of rapid global supply, as demonstrated during the COVID-19 pandemic. Yellow fever is a mosquito-borne viral hemorrhagic disease endemic in parts of Africa and Latin America, and although an effective live attenuated vaccine exists, its use is limited by safety and eligibility restrictions. Moreover, large outbreaks continue to expose critical challenges, such as an insufficient vaccine supply, reliance on fractional dosing, and slow and difficult-to-scale manufacturing processes. Here, we report the design, development and in vivo immunogenicity of multiple yellow fever virus (YFV) antigen constructs based on the pre-membrane (prM) and envelope (E) proteins—with or without the transmembrane domain (TM or ΔTM)—delivered using the ChAdOx1 adenoviral vector.
Methods:
Four ChAdOx1 YF vaccines were developed, and immunogenicity was evaluated. The efficacy of the full-length YF envelope vaccine was also tested in Balb/c mice.
Results/Conclusions:
In contrast to previously described orthoflavivirus vaccines on the same platform, the full-length antigen elicited superior immunogenicity and conferred protection against intracranial challenge with the YF17D virus in mice. Notably, this protection was comparable to that induced by the licensed YF17D vaccine, highlighting the promise of this platform as a next-generation yellow fever vaccine candidate.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 1.4MB, Terms of use)
-
- Publisher copy:
- 10.3390/vaccines14030273
Authors
+ European Union
More from this funder
- Funder identifier:
- https://ror.org/019w4f821
- Grant:
- 101137459 (Yellow4FLAVI)
- Programme:
- Horizon Europe Programme
- Publisher:
- MDPI
- Journal:
- Vaccines More from this journal
- Volume:
- 14
- Issue:
- 3
- Article number:
- 273
- Place of publication:
- Switzerland
- Publication date:
- 2026-03-20
- Acceptance date:
- 2026-03-18
- DOI:
- EISSN:
-
2076-393X
- Pmid:
-
41893809
- Language:
-
English
- Keywords:
- Pubs id:
-
2395875
- Local pid:
-
pubs:2395875
- Source identifiers:
-
W7138989587
- Deposit date:
-
2026-04-01
- ARK identifier:
Terms of use
- Copyright holder:
- Ulaszewska et al.
- Copyright date:
- 2026
- Rights statement:
- ©2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record